Search clinical trials for: Recombinant activated factor VII

Total 44951 results

Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Hemophilia A

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor

Hemophilia A | Hemophilia B

China
Emory University
Octapharma

Recruiting

Treatment of Hemophilia A Patients With FVIII Inhibitors (MOTIVATE)

Hemophilia A

United States, Germany
Joseph Broderick, MD
Novo Nordisk A/S; National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial (FASTEST)

Intracerebral Hemorrhage

United States, Canada, Germany, Japan, Spain, United Kingdom
University Hospital, Bordeaux

Completed

Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) (TAAS)

Glanzmann Thrombasthenia

France
Novo Nordisk A/S

Completed

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States
CSL Behring

Terminated

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Georgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
Universiti Sains Malaysia

Completed

Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

Massive Hemorrhage | Massive Blood Loss | Massive Blood Transfusion; Thrombocytopenia

Malaysia
Novo Nordisk A/S

Completed

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United States, Sweden, Serbia, Turkey, United Kingdom, Malaysia, Brazil, Former Serbia and Montenegro, Japan, South Africa
Centre Hospitalier Universitaire de Nīmes

Terminated

Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy

Post Partum Haemorrhage | Health Care Cost
University of Cincinnati
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

The Spot Sign for Predicting and Treating ICH Growth Study (STOP-IT)

Intracerebral Hemorrhage

United States, Canada
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

Congenital Bleeding Disorder | Glanzmann's Disease

Japan
CSL Behring

Completed

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Congenital Coagulation Factor VII Deficiency

Netherlands, Norway
Novo Nordisk A/S

Terminated

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

United States
Novo Nordisk A/S

Completed

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Trauma | Acquired Bleeding Disorder

United States, Canada
Novo Nordisk A/S

Completed

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's Disease

France
Novo Nordisk A/S

Completed

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

Spain, Sweden, Singapore, Norway, Italy, Switzerland, Australia, Austria, Belgium, Canada, Denmark, Finland, Germany, Netherlands, United Kingdom
Novo Nordisk A/S

Completed

Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France
Novo Nordisk A/S

Completed

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients

Trauma | Acquired Bleeding Disorder

Germany, Austria, Israel, France, Canada, Singapore, South Africa, Australia, United Kingdom
Novo Nordisk A/S

Completed

Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

Germany, Sweden, United Kingdom, Spain, Canada, Australia, France
Novo Nordisk A/S

Completed

Use of NovoSeven® in Active Variceal Bleeding

Cirrhosis | Acquired Bleeding Disorder

Germany, United Kingdom, Spain, Taiwan, France, Italy, Austria, Czech Republic, Poland, Denmark, Finland, Hong Kong
Novo Nordisk A/S

Completed

Use of Activated Recombinant FVII in Spinal Surgery

Spinal Fusion | Acquired Bleeding Disorder

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

Cirrhosis | Acquired Bleeding Disorder

Taiwan, Thailand, China
Novo Nordisk A/S

Completed

Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction

Trauma | Acquired Bleeding Disorder

United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

Other Haemostasis Disorder | Haemorrhagic Cystitis

United States
Novo Nordisk A/S

Terminated

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

Acquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary Bypass

United States, Spain, Germany, Sweden, United Kingdom, Argentina, Italy, Brazil, Denmark, France, India, Malaysia, Singapore, South Africa
Novo Nordisk A/S

Completed

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United Kingdom, Spain, Israel, Poland, Turkey, Hungary
Novo Nordisk A/S

Completed

Treatment of Congenital Factor VII Deficiency (F7CONDEF)

Congenital Bleeding Disorder | Congenital FVII Deficiency

Slovakia, Israel, Spain, India, Iran, Islamic Republic of, Pakistan, Turkey, Germany, Serbia, Italy, Greece, Thailand, France, United States, Hong Kong, Venezuela
Novo Nordisk A/S

Completed

Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease

Acquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary Bypass

Australia
Novo Nordisk A/S

Completed

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage (FAST)

Acquired Bleeding Disorder | Intracerebral Haemorrhage

United States, Spain, Germany, Sweden, Netherlands, Austria, Belgium, Singapore, Taiwan, Israel, Italy, Denmark, Australia, Thailand, France, Norway, Croatia, Hong Kong, China, Canada, Switzerland, Brazil, Finland
Novo Nordisk A/S

Completed

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States
Novo Nordisk A/S

Completed

Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury

Trauma | Acquired Bleeding Disorder

India, Spain, Canada, Finland, Germany, Israel, Italy, Netherlands, Singapore, Switzerland, Taiwan
Novo Nordisk A/S

Completed

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United States, Spain, Brazil, Philippines, South Africa, Poland, Turkey, Romania, Bulgaria, Russian Federation, Argentina
Novo Nordisk A/S

Completed

Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain, Italy, Greece, Germany, United Kingdom
Novo Nordisk A/S

Completed

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Healthy | Congenital Bleeding Disorder

United States
Novo Nordisk A/S

Completed

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

Finland, Singapore, Australia, Spain, Denmark, Germany, Italy, Taiwan, United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

Israel, Sweden, United Kingdom, Germany, Switzerland, France, Spain, Italy, Thailand, Denmark, United States, Poland, Finland, Singapore, Australia, Austria
Novo Nordisk A/S

Completed

Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

Acquired Bleeding Disorder | Dengue Haemorrhagic Fever

Malaysia, Philippines, Thailand
Novo Nordisk A/S

Completed

Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (ONE)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Saudi Arabia, Algeria, Turkey, Germany, Poland, Netherlands, Italy, Belgium, South Africa, United Kingdom, Sweden, Austria, Portugal, France, Czech Republic, Venezuela
Novo Nordisk A/S

Completed

PROPACT: Retrospective Prophylaxis Patient Case Collection (PROPACT)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Slovakia, Spain, Argentina, Germany, Croatia, Italy, Canada, United Kingdom, Ireland, Sweden, France, United States, Czech Republic, Switzerland
Novo Nordisk A/S

Completed

Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany (WIRK)

Congenital Bleeding Disorder | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's Disease

Germany
Novo Nordisk A/S

Completed

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Healthy | Haemostasis

United States
Novo Nordisk A/S

Completed

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States, Denmark, France, United Kingdom
Novo Nordisk A/S

Terminated

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Healthy | Haemostasis

United States
Novo Nordisk A/S

Completed

Factor VIIa in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

Japan
Novo Nordisk A/S

Completed

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX (DOSE)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States
Novo Nordisk A/S

Completed

Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Novo Nordisk A/S

Completed

Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain
Novo Nordisk A/S

Completed

A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom

Search clinical trials for: Recombinant activated factor VII

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations